Piramal Pharma's Q1 FY 2025-26 Quarter Results
- 29 Jul 2025
Result Summary
- Piramal Pharma Ltd reported a 22.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 1.1%.
- Its expenses for the quarter were down by 9.5% QoQ and up 3.5% YoY.
- The net profit decreased 180.7% QoQ and decreased 7.8% YoY.
- The earnings per share (EPS) of Piramal Pharma Ltd declined at 0.6 during Q1 FY 2025-26.
Financial Statments for Q1 FY 2025-26
| (₹ crores) | Q1FY26 | Q4FY25 | Q1FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1992.11 | 2578.74 | 1970.68 | -22.7% | 1.1% |
Total Expenses | 2110.44 | 2332.78 | 2038.16 | -9.5% | 3.5% |
Profit Before Tax | -97.59 | 215.44 | -67.48 | -145.3% | 44.6% |
Tax | 2.68 | 126.21 | 43.56 | -97.9% | -93.8% |
Profit After Tax | -81.70 | 101.27 | -88.64 | -180.7% | -7.8% |
Earnings Per Share | -0.60 | 0.80 | -0.70 | -175.0% | -14.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Piramal Pharma Ltd is a prominent entity in the pharmaceutical industry. The company is involved in the development and production of a wide range of pharmaceutical products and healthcare solutions. Piramal Pharma operates through various segments that include contract development and manufacturing, critical care, and consumer healthcare products. The company has a significant presence in both domestic and international markets, focusing on both generic and branded formulations. Any recent major developments in the company or industry are not provided in the current dataset.
Revenue
In Q1FY26, Piramal Pharma Ltd reported a total income of ₹1,992.11 crores. This represents a quarter-over-quarter (QoQ) decrease of 22.7% from ₹2,578.74 crores reported in Q4FY25. Compared to the same quarter in the previous year, Q1FY25, where the total income was ₹1,970.68 crores, there is a year-over-year (YoY) increase of 1.1%. The data indicates a significant reduction in total income from the previous quarter, while a marginal increase is noted when compared to the same period last year.
Profitability
The company's profitability indicators show a mixed performance. In Q1FY26, the profit before tax was recorded at a loss of ₹97.59 crores, contrasting with a profit of ₹215.44 crores in Q4FY25. This indicates a QoQ decrease of 145.3%. Compared to Q1FY25, where the loss was ₹67.48 crores, there is a 44.6% YoY increase in losses. The profit after tax for Q1FY26 also reflects a negative figure of ₹81.70 crores, down from a profit of ₹101.27 crores in Q4FY25, indicating a QoQ decrease of 180.7%. When compared to a loss of ₹88.64 crores in Q1FY25, there is a YoY improvement of 7.8%. Earnings per share (EPS) in Q1FY26 was at a negative ₹0.60, compared to ₹0.80 in Q4FY25 and a negative ₹0.70 in Q1FY25, demonstrating a QoQ decrease of 175.0% and a YoY improvement of 14.3%.
Operating Metrics
The total expenses for Piramal Pharma Ltd in Q1FY26 stood at ₹2,110.44 crores, which is a 9.5% reduction from ₹2,332.78 crores in Q4FY25. Compared to Q1FY25, where expenses were ₹2,038.16 crores, there is a 3.5% increase YoY. The tax expenses for Q1FY26 were recorded at ₹2.68 crores, showing a significant decrease of 97.9% QoQ from ₹126.21 crores in Q4FY25. When compared to Q1FY25's tax expense of ₹43.56 crores, there is a YoY decrease of 93.8%. These operating metrics highlight changes in expense management and tax liabilities over the quarters.